Research
Needham Initiates Immix Biopharma at Buy With $21 Price Target
Immix Biopharma (IMMX) has an average rating of buy and mean price target of $19.94, according to analysts polled by FactSet.
$IMMX
$IMMX
6 stories mentioning IMMXUpdated 53d ago
Every FINWIRES story that references IMMX, newest first.
What are analysts saying about IMMX?
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
What's the latest news on IMMX?
Research
BofA Initiates Immix Biopharma at Buy With $27 Price Target
Immix Biopharma (IMMX) has an average rating of buy and mean price target of $19.79, according to analysts polled by FactSet.
$IMMX
Sectors
Sector Update: Healthcare Stocks Decline Premarket Thursday
Healthcare stocks were declining premarket Thursday, with the iShares Biotechnology ETF (IBB) 1% lower and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1%.Immix Biopharma (IMMX) shares were up more than 6% after the company said it achieved a 95% complete response rate in a phase 1b/2 trial evaluating NXC-201 for the treatment for relapsed/refractory AL Amyloidosis.Nanobiotix (NBTX) launched a global follow-on offering of 75 million euros ($87.2 million), the clinical-stage biotechnology company said. Nanobiotix stock was down more than 5% pre-bell.Relay Therapeutics (RLAY) shares were up more than 10% after the company said it priced a public offering of 22.9 million common shares at $12 each.
$IBB$IMMX$NBTX$RLAY$XLV
Sectors
Sector Update: Healthcare
Healthcare stocks were steady premarket Thursday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) down a slight 0.1%.Immix Biopharma (IMMX) shares were nearly 8% higher after the company said it achieved a 95% complete response rate in a phase 1b/2 trial evaluating NXC-201 for the treatment for relapsed/refractory AL Amyloidosis.
$IMMX
Research
Update: Mizuho Keeps Price Target on Immix Biopharma to $15, Maintains Outperform Rating
(Updated to keep price target unchanged).Price: $8.57, Change: $-0.04, Percent Change: -0.41%
$IMMX
Wire
Mizuho Adjusts Price Target on Immix Biopharma to $15 From $10, Maintains Outperform Rating
Mizuho Adjusts Price Target on Immix Biopharma to $15 From $10, Maintains Outperform Rating
$IMMX
